These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19923038)

  • 41. PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease.
    Landreth G
    Exp Neurol; 2006 Jun; 199(2):245-8. PubMed ID: 16733054
    [No Abstract]   [Full Text] [Related]  

  • 42. Lichen planopilaris treated by the peroxisome proliferator activated receptor-γ agonist pioglitazone: lack of lasting improvement or cure in the majority of patients.
    Spring P; Spanou Z; de Viragh PA
    J Am Acad Dermatol; 2013 Nov; 69(5):830-832. PubMed ID: 24124823
    [No Abstract]   [Full Text] [Related]  

  • 43. Mixing of the old with the new: nanoparticle-mediated pioglitazone delivery to enhance therapeutic neovascularization.
    Sheng CC; Hong CC
    Arterioscler Thromb Vasc Biol; 2012 Oct; 32(10):2337-8. PubMed ID: 22972937
    [No Abstract]   [Full Text] [Related]  

  • 44. The potential role of ‘non-rheumatic’ therapies in rheumatic disease.
    Massarotti EM; Solomon DH
    Arthritis Res Ther; 2013; 15(6):124. PubMed ID: 24229459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Using genetics to enable studies on the prevention of Alzheimer's disease.
    Crenshaw DG; Gottschalk WK; Lutz MW; Grossman I; Saunders AM; Burke JR; Welsh-Bohmer KA; Brannan SK; Burns DK; Roses AD
    Clin Pharmacol Ther; 2013 Feb; 93(2):177-85. PubMed ID: 23249780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pioglitazone, Nuclear Receptors, and Aerodigestive Prevention.
    Ondrey FG
    Cancer Prev Res (Phila); 2019 Oct; 12(10):641-644. PubMed ID: 31537582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thiazolidinedione as an alternative to facilitate oral administration in geriatric patients with Alzheimer's disease.
    Silva-Abreu M; Gonzalez-Pizarro R; Espinoza LC; Rodríguez-Lagunas MJ; Espina M; García ML; Calpena AC
    Eur J Pharm Sci; 2019 Mar; 129():173-180. PubMed ID: 30639402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease.
    Geldmacher DS; Fritsch T; McClendon MJ; Landreth G
    Arch Neurol; 2011 Jan; 68(1):45-50. PubMed ID: 20837824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
    Gold M; Alderton C; Zvartau-Hind M; Egginton S; Saunders AM; Irizarry M; Craft S; Landreth G; Linnamägi U; Sawchak S
    Dement Geriatr Cogn Disord; 2010; 30(2):131-46. PubMed ID: 20733306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.
    Harrington C; Sawchak S; Chiang C; Davies J; Donovan C; Saunders AM; Irizarry M; Jeter B; Zvartau-Hind M; van Dyck CH; Gold M
    Curr Alzheimer Res; 2011 Aug; 8(5):592-606. PubMed ID: 21592048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease.
    Searcy JL; Phelps JT; Pancani T; Kadish I; Popovic J; Anderson KL; Beckett TL; Murphy MP; Chen KC; Blalock EM; Landfield PW; Porter NM; Thibault O
    J Alzheimers Dis; 2012; 30(4):943-61. PubMed ID: 22495349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.
    Mandrekar-Colucci S; Karlo JC; Landreth GE
    J Neurosci; 2012 Jul; 32(30):10117-28. PubMed ID: 22836247
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pioglitazone for the treatment of Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Investig Drugs; 2017 Jan; 26(1):97-101. PubMed ID: 27885860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustained 4-year cognitive and functional response in early Alzheimer's disease with pioglitazone.
    Read S; Wu P; Biscow M
    J Am Geriatr Soc; 2014 Mar; 62(3):584-6. PubMed ID: 24628640
    [No Abstract]   [Full Text] [Related]  

  • 55. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
    Craft S; Baker LD; Montine TJ; Minoshima S; Watson GS; Claxton A; Arbuckle M; Callaghan M; Tsai E; Plymate SR; Green PS; Leverenz J; Cross D; Gerton B
    Arch Neurol; 2012 Jan; 69(1):29-38. PubMed ID: 21911655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.
    Miller BW; Willett KC; Desilets AR
    Ann Pharmacother; 2011 Nov; 45(11):1416-24. PubMed ID: 22028424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathology.
    Papadopoulos P; Rosa-Neto P; Rochford J; Hamel E
    PLoS One; 2013; 8(7):e68612. PubMed ID: 23874687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of intranasal insulin on cognitive function: a systematic review.
    Shemesh E; Rudich A; Harman-Boehm I; Cukierman-Yaffe T
    J Clin Endocrinol Metab; 2012 Feb; 97(2):366-76. PubMed ID: 22162476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.
    Tzimopoulou S; Cunningham VJ; Nichols TE; Searle G; Bird NP; Mistry P; Dixon IJ; Hallett WA; Whitcher B; Brown AP; Zvartau-Hind M; Lotay N; Lai RY; Castiglia M; Jeter B; Matthews JC; Chen K; Bandy D; Reiman EM; Gold M; Rabiner EA; Matthews PM
    J Alzheimers Dis; 2010; 22(4):1241-56. PubMed ID: 20930300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis.
    Cheng H; Shang Y; Jiang L; Shi TL; Wang L
    Int J Neurosci; 2016; 126(4):299-307. PubMed ID: 26001206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.